Try our Advanced Search for more refined results
Life Sciences - May, 2018
319 articles
- Ex-Katten Atty's Inflation Claim Lacks Evidence, Feds Say
- ITC To Investigate Chinese Cholesterol Test Strips
- Anthem, Express Scripts Fight Pricing Suit In 2nd Circ.
- 6th Circ. Affirms Freeze On Disbarred Fen-Phen Atty's Assets
- 'Copycats' Can't Push Zetia Antitrust MDL To NY, Panel Told
- 1 Firm Leaps Ahead In May As IPO Market Gathers Steam
- FDA Targets Anti-Generic Foot-Dragging By Big Drugmakers
- SEC Sues Hemp Health Products Co. Over Illicit Stock Sales
- Feds To Depose 12 New Docs In FCA Case Over Hep B Tests
- NY Doc Gets 4 Years For Part In $100M Referral Bribe Scheme
- 'Opioid Babies' Need Separate Track In MDL, Attys Say
- BigLaw Blogs In A Post-GDPR Marketing Universe
- Pa. Pharmacy Owners Ink $3.2M False Billing Settlement
- Boston Scientific Enters $608M Transfer Pricing Deal With IRS
- HHS Medicare Drug Reimbursement Cap Illegal, Suit Says
- Opioid MDL Order Shows Need For Broad Funding Disclosure
- Investors Clinch $18M Deal With Aveo, With 30% For Attys
- Ixchel Asks 9th Circ. To Revive Biogen Antitrust Claims
- Jury Must Hear Wife's Role At Insider Trades Trial, Feds Say
- Groups Urge 9th Circ. To Keep ACA Birth Control Rules Halted
- $395K Atty Fees In Clovis Director Pay Deal Get Chancery OK
- Investors Spar For Lead In Mass. Bioscience Class Action
- FDA Issues Challenge For New Tech To Fight Opioid Crisis
- Insys Sales Rep Pleads Guilty To Opioid Kickback Scheme
- FTC, NY Can't Revive Memory-Booster Suit, 2nd Circ. Told
- GSK, Reed Smith Atty's Widow Spar Over Case's Fiscal Impact
- Blood Test Co. Says Rival Falsely Advertised FDA Status
- Deals Rumor Mill: Allergan, Ant Financial, Oman Oil
- FDA's Youth E-Cig Blitz Could Go Much Further
- The Potentially Far-Reaching Impact Of Sports Betting Case
- J&J Faces Start Of Latest Asbestos-In-Talc Trial In Calif.
- Calif. Appeals Court Shuts Down Biotech Shareholder Suit
- Fla. Gov. Asked To Drop Smokable Med. Marijuana Appeal
- Suits Show Conflict Even At BigLaw's Best Places For Women
- Reform Or Retreat? UK Firms Eye Next Steps On Pay Data
- How Women Are Changing The Law Firms They Lead
- The Best Law Firms For Female Partners
- Duane Morris Adds 7 IP Attys From Vedder Price
- Opioid Suit Against McKesson Doesn't Fit In MDL, Tribe Says
- Bayer, Monsanto Win US Clearance For $62B Deal
- Besins Cut Loose From Testosterone Replacement MDL
- Biotech Startup, Music Streamer Launch IPOs Totaling $158M
- Medical Supplier Pays Feds $1.9M To End FCA Suit
- BakerHostetler Nabs Cairncross Corporate Finance Pro
- High Court Won't Hear Abilify Whistleblowers' FCA Claims
- Shire Stockholders Sue AbbVie Over Failed Merger
- The 2018 Law360 Glass Ceiling Report
- Alibaba Sells Pharmacy Assets To Health Unit For $1.35B
- Analyzing The Economics Of Litigation Funding
- Rule 23 Changes: How Electronic Notice Can Save Money
- Law360's Glass Ceiling Report, By The Numbers
- The Best Law Firms For Female Attorneys
- Law360's Pro Say: Why Are All The Partners Still Men?
- How We Got Here: A Look Back At Trailblazing Women In Law
- What Does Gender Parity In The Legal Industry Look Like?
- Stakes High As GSK Takes Generics Liability Row To 7th Circ.
- Printed Matter Doctrine Case Could Offer New Patent Attack
- Jury Awards $1.2M Over Vein Perforated By Medical Device
- 5 Flash Points As FDA Gets Earful On Compounding Guidance
- Biotechs Lead Wave Of New IPOs Filling June Pipeline
- Weeks Before Oral Args, Mylan Drops AstraZeneca IP Appeal
- Jury Deadlocks In Latest Trial Over J&J Talc And Asbestos
- Buyers Can't Bar Testimony In Teva Pay-For-Delay Suit
- Self-Policing Animal Research: Another Bad Idea From USDA
- A Wish For Nonexistent Cheap Drugs Is Not Standing To Sue
- J&J Claims $70M Award In Surgical Stapler Case Is Unjustified
- Asbestos In J&J Talc Killed 30-Year-Old Atty, Jury Told
- Latham, Goodwin Lead 2 Biotech IPOs Raising $227M
- Procaps Hits Carlton Fields With $15M Malpractice Suit
- Howmedica's Decade Of Misconduct Won Zimmer $13M Fees
- Chinese Co.'s Suit Over GSK Probe Tied To US, 3rd Circ. Told
- Hatch-Waxman Post-TC Heartland: What You Need To Know
- Keys To Protecting Communications With Litigation Funders
- Pfizer Pays $24M To End Medicare Copay Kickback Claims
- Jury Hits J&J With $4M Punitives In Talc Cancer Trial
- J&J Hit With $21.7M Talc Asbestos Cancer Verdict In Calif.
- SG Urges High Court To Take Up Merck's Fosamax Appeal
- NY Doc Convicted For Distributing Opioids That Killed 2
- Dexcom Hit With Atty Fees For 'Bad Faith' Patent Suit
- Fed. Circ. Upholds Most Of Bovine Breeding Patent Verdict
- J&J Talc Supplier Challenges Evidence In $117M Verdicts
- FDA Wants Risky OTC Teething Treatments Pulled Off Market
- 'Queen Of Toxic Torts' Leaves Quinn Emanuel For Dechert
- UCB's Epilepsy Drug Patent Win Upheld By Fed. Circ.
- Biosimilars Imperiled By Big Drug Rebates, FDA Chief Warns
- Impax Dismissal Offers Clues On Pay-For-Delay Under Actavis
- CORRECTED: Convictions Don't Mean Valeant Is Off The Hook
- Teva Urges Justices To Reject Fed. Circ. On-Sale Bar Appeal
- Norton Rose Loses 14 Health, Life Sci Attys To Reed Smith
- Cherokees Slam Drug Cos.' Bid To Pause Opioid Suit
- Trade Rep Hints At More CFIUS Scrutiny Of Biotech Deals
- Lessons From FDA Draft Guidance On Multifunctional Devices
- No Asbestos In J&J Talc Mines, SC Mesothelioma Jury Hears
- Pa. Panel Revives Suit Linking Man's Leukemia To Pesticides
- Ill. Robitussin Buyers Slam Bid To Toss Nationwide Claims
- Ex-Insys Execs Rail Against 'Inflammatory' RICO Indictment
- House Sends 'Right To Try' Treatments Bill To Trump
- Covington Picks Up 2 Kirkland Partners To Lead PE Practice
- Express Scripts Beats Investor Suit Over Anthem Disclosures
- GSK Gets Generic Suits Tossed From Zofran MDL
- 9th Circ. Urged To Keep ACA Birth Control Rules Blocked
- FDA Warning Wire: Rodent Feces At Mass. Candy Plant
- Sanofi Must Divulge Docs In FCA Fight Over Cancer Drug
- CPSC Steps Up Action On Safe Product Packaging Standards
- Ex-Manager, CEO Convicted In $9.7M Valeant Kickback Plot
- Deal In CVS False Ad Suit Shouldn't Get OK, Judge Says
- Sonoma Pharma Can Likely Pursue Trade Secret Claims
- Tribe Says It's Not Just 'Collecting A Check' From Patents
- DLA Piper Picks Up NJ Corporate Atty From Morgan Lewis
- Pillsbury Adds IP Duo In Calif. To Lead Taiwan Practice
- Calif. County Must Face $77M Hemp Seizure Suit, Court Told
- High Court Won't Look At 3rd Circ. Ruling On Eyedrop Size
- Justices Turn Away Solvay FCA Off-Label Marketing Case
- Gilead Again Pushes To Block Truvada Generic
- Introducing The Legal Industry To Millennial Business Owners
- Pa. Appeals Court Urged To OK Philly Mesh Case Jurisdiction
- FTC Admin. Judge Says Endo-Impax Opana Deal Is Lawful
- Fla. Argues To Keep Stay During Pot 'Right To Grow' Appeal
- Tribes Insist On Being Heard In Noisy Opioid MDL
- DEA Drops Enforcement Order Against Opioid Distributor
- Taxation With Representation: Gibson, Freshfields, Wachtell
- NantKwest Investors See Suit Over IPO Tossed Over Standing
- Illumina Can't Enforce Fetal DNA Testing Patent, Natera Says
- 9th Circ. Revives Vitamin E Labeling Row Over Heart Claims
- 7 Firms To Guide IPO Lineup Projected To Surpass $1.2B
- Praxair And The Printed Matter Doctrine
- Advertiser Self-Regulation And Class Actions: Part 3
- Duke Wants Sanctions Over FCA Whistleblower's Convos
- Highlights Of Proposed Medicare Payment And Policy Rules
- A Proposed Approach For High Court In Vitamin C Case
- $9.7M Valeant Payment Was Legal, Ex-Execs Argue In Closing
- FDA Shames Anti-Generic Tactics, Putting Onus On Congress
- Ex-NJ Lab Workers Sentenced In $100M Bribery Scheme
- Exclusivity 'Didn't Require Success,' Amgen Tells DC Circ.
- Osco Drug Sued Over 20 Faxes A Day Promoting Drug Refills
- Mass. Doctor's Kickback Convictions Are Fair, Judge Says
- Deals Rumor Mill: Anglo, Aspen, Thoma Bravo
- Advertiser Self-Regulation And Class Actions: Part 2
- A Chat With Perkins Practice Management Chief Toby Brown
- GSK, Zofran Users To Pick 16 Potential MDL Bellwether Cases
- A Look Inside Trump's 4-Point Plan For Curbing Drug Prices
- Titan Of The Plaintiffs Bar: The Lanier Law Firm's Mark Lanier
- Retailers Led By Walgreens Sue Allergan Over Restasis IP
- Biolitec Counsel Can't Dodge Sanction For Stonewalling
- Fed. Circ. Nixes More Of Inomax Patent After PTAB Review
- Church & Dwight To Face Trimmed Supplement Labeling Row
- Fed. Circ. Upholds Endo's Opioid Patent Win Against Generics
- Feds Show Valeant Jury Spending Records, Doctored Emails
- Deals Rumor Mill: Tianqi, SoftBank, CVC
- Novartis, Par Hit With Pay-For-Delay Suit Over Exforge
- Ill. Jury Finds For AbbVie In AndroGel Bellwether Trial
- Tennis Org Wants $10M Blood Test Injury Suit Arbitrated
- Man Asks Fla. Justices For Right To Grow Pot During Appeal
- DOJ, Microsoft Urge Fed. Circ. To Find Tribes Can Face IPRs
- FCA Questions That High Court May Address Next Term
- 3 Firms Guide PE-Backed Hearing Aid Co.'s €7B Merger
- Advertiser Self-Regulation And Class Actions: Part 1
- No Smoke But Alarms Are Ringing: Insurance For E-Cigarettes
- Why Won't Judicial Nominees Affirm Brown V. Board Of Ed?
- Fed. Circ. Applies Teva Deference In 2 Types Of Cases
- Wachtell Reps Zoetis In $2B Deal For Animal Diagnostics Co.
- Novartis GC Steps Down After News Of Cohen Payments
- The Lawyers' Guide To Cloud Computing
- Tribal Patent Pacts An 'Assault' On IPR System, Fed. Circ. Told
- Defense Buffeted By Tough Rulings In Valeant Kickback Trial
- ZimmerBiomet Scores $13M In Fees In Howmedica IP Fight
- GSK Says W.Va. High Court Opinion Backs 7th Circ. Appeal
- Dartmouth Says PTAB Abused Discretion In Post-SAS Ruling
- Ex-Katten Atty Says Gov't Inflating Retrophin Losses
- FDA Clears Hospira's Biosimliar Of Amgen's Epogen
- 3rd Circ. Already OK'd Lipitor State Claims, Health Plans Say
- 6 States Sue Purdue Over Alleged Deceptive Opioid Marketing
- Insys Bribed Docs To Write Opioid Scripts, DOJ, 6 States Say
- Chancery Grants Class $3M In Legal Fees For Sorrento Suit
- Ex-Herbalife Sellers Fight Bid To Send $1B RICO Suit To Calif.
- CVS Seeks Exit From Proposed HIV Privacy Class Action
- FDA Warning Wire: Pesticides, Poisoning, YouTube Promos
- Class Attys Want $25M From $72.5M Medicis, Impax Deals
- Titan Of The Plaintiffs Bar: Seeger Weiss' Christopher Seeger
- Opioid Legislation May Expand Telehealth Coverage
- Keys To FDA Advisory Panel Prep For Device Makers
- Emerging Enforcement Trends For Patient Support Programs
- Alleged Valeant Betrayer's Boss Testifies He Was 'Concerned'
- Brand-Name Drug Cos. Not Liable For Generics' Tags In W.Va.
- Top Senate Dem Wants Info On Cohen-Novartis Dealings
- Fed. Circ. Upholds Toenail Drug IP Nix After Bass Challenge
- Fintech Co. GreenSky Tops 3 IPO Launches Totaling $951M
- J&J Can't Arbitrate Applicant's Background Check Claims
- USTR Prepares For Onslaught Of China Tariff Opposition
- Canada's Aurora Cannabis Scoops Up R&D Co. For $2.5B
- Recovering Lawyers' Lost Position Of Independence
- Overlooked Changes To Patent Cooperation Treaty Practice
- Texas Plans Opioid Deception Suit, Opposes State MDL
- BioChemics Not Covered For SEC Action, Axis Tells 1st Circ.
- Fed. Circ. Tells PTAB To Look Again At Eye Solution Patent
- Medical Device Co. Owes $2M For Contract Breach, Suit Says
- Trump Vows Cheaper Drugs 'Very Soon,' But That's Unlikely
- 23andMe Hits Ancestry.com With Patent Suit Over DNA Kit
- $45M Drug Milestone Suit Against Shire Kept Alive In Del.
- Bayer, Merck Sunblock SPF Suit Sent Back To State Court
- Dozens Of Cases Cut From Testosterone Replacement MDL
- Avee's Abbott Escrow Row Partly Nixed, But Open To Change
- Fed. Circ. Affirms Dismissal Of AIDS Drug Antitrust Case
- Taxation With Representation: Davis, Freshfields, Wachtell
- Health Hires: Katten, Seyfarth, Holland, Dechert, K&L Gates
- 'Anti-Aging Miracle' Does Nothing Of The Sort, Suit Says
- Lack Of Sameness Doomed INRatio Class Certification
- NJ Justices OK Centralizing Abilify Side-Effect Suits
- Trump To Unveil 4-Point Plan For Curbing Drug Prices
- Actiq Off-Label Marketing Suit Preempted, Pa. Panel Affirms
- NantKwest Says Investors Lack Standing For Some Claims
- Opioid MDL Judge Says Litigation Track Is A Settlement Aid
- 3 Firms Win 25% Fee Approval For $3.5M Ariad Deal
- Wachtell Reps Eli Lilly In $1.6B Deal For Oncology Drug Co.
- Scientist Asks 3rd Circ. To Rehear $5.8M Royalty Tax Case
- Firms Ask To Consolidate NJ Zostavax Suits Against Merck
- 8 Reasons To Take A Fresh Look At Your Law Office Lease
- Pomerantz, Shapiro Seek $5M Fees For $18M Aveo Stock Deal
- Shire Defends $2.4M Fee Request In Adderall Generic Row
- DOJ Sues To Stop Clinics' Unapproved Stem Cell Treatments
- Ex-Valeant Worker's Emails Show Double-Dealing, Jury Hears
- Attys Brawl Over Hospital Choice For Opioid MDL Bellwether
- A General Counsel's Tips For Succeeding As A New Associate
- Bristol Meyers, Pfizer Didn't Violate TCPA, 6th Circ. Says
- Pharma CEO Pleads Not Guilty Of $1.5M Fraud, For Now
- Thoratec Investors Win Cert. In Revived Stock-Drop Suit
- Novartis Says It Paid Michael Cohen $1.2M, Received Nothing
- CEO Asks 1st Circ. To Nix $3M 'Little Red Hen' Payout
- Patients Paid When Takeda Hid Actos Cancer Risks, Suit Says
- $117M Verdicts In J&J Talc Case Must Stand, Couple Says
- Neb. Tribes Sue Pharma Cos. Over 'Havoc' From Opioid Crisis
- VC-Backed Biotech, Louisiana Bank Price IPOs Raising $209M
- Ex-Pharmacist Denied Meningitis Acquittal Bid Amid Appeal
- Digital Medicine Co. Reaps $55M In Temasek-Led Fundraising
- Pay Attention To The Law And The Science Of Cannabidiol
- Some Soon-Shiong Claims Kept Alive In $47M Cash Tap Suit
- Jazz Pharmaceuticals To Pay $57M To End DOJ Inquiry
- Unclear If Shkreli's Attys Can Rep His Old Co., Judge Says
- Genentech Defends Herceptin Dosing Patents Before PTAB
- Drug Execs Deny Blame For Role In Opioid Crisis
- Widow Says Atty's Duty Included Safeguarding Frozen Sperm
- DEA Must Divulge National Data In Opioid MDL, Judge Rules
- 30 Calif. Counties Suing Opioid Makers, Distributors
- GSK Can't Make Hagens Berman Pay Special Master Fees
- Deals Rumor Mill: Walmart, Comcast, Bunge
- States Get 'Modest' Tax Help From Cannabis, Moody's Says
- Valeant To Pay Calif. Insurance Dept. $1.9M Over Philidor Ties
- Vanda Sues 2 Pharma Cos. Over Sleep Disorder Drug Patents
- McCarter & English Lands Ex-McDermott Patent Pro In Boston
- Arnold & Porter Sanctioned In Boston Scientific IP Case
- UK Cancer Biotech, Trucking Co. File IPOs Totaling $200M
- Diagnostics Co. Urges Justices To Deny Mayo Challenge
- Korean Investment Firm Pays $130.5M For GSK's Philly HQ
- Smarter, Faster, Stronger: A New Suite Of VC Model Docs
- A Cautiously Optimistic Diagnosis For Patent Eligibility
- Takeda Inks £46B Shire Takeover After Multiple Offers
- RxStrategies Says CVS, Rival Swiping Its Customers
- Endo Shareholders Fight Bid To Toss Opioid Safety Suit
- Opioid MDL Attys Must Disclose Outside Funding, Judge Says
- Fed. Circ. Affirms Damages In X-Ray Patent Row
- Drug Cos. Can Add Support To Pause Cherokee Opioid Suit
- Opana ER MDL Buyers Want Impax Docs About Endo Deal
- CytRx Investors Seek OK On $5.75M Stock Drop Settlement
- No Kickback Sanctions For Ostomy Samples, Watchdog Says
- DEA's Proposed Opioid Limits Meet Industry Resistance
- PTAB Won't Revisit Patent For Astellas Bladder Drug
- Boehringer Scores 2nd Bellwether Win In Conn. Pradaxa Suit
- Judging A Book: Berzon Reviews 'We The Corporations'
- Diabetic Care RX Case Is A Warning Sign For Private Equity
- What ABA's Position On Harassment Means For Employers
- Inside The New GMO Labeling Disclosure Proposal
- Law360 Reveals Titans Of The Plaintiffs Bar
- Titan of the Plaintiffs Bar: Baum Hedlund's R. Brent Wisner
- FDA Fights Challenges To E-Cig Regulations In DC Circ.
- Insurer Asks 4th Circ. To Nix $87M Heparin Coverage Ruling
- SEC Sues Ex-Biotech Exec Over $21M Boiler Room Scheme
- FDA Can't Evade Prior Orphan Drug Ruling, Eagle Says
- Kessler Topaz Wins Lead In Cancer Drug Stock-Drop Suit
- Becton At Center Of Antitrust Suit Over Syringes, Catheters
- DC Circ. Mulls $1.6B Cut To Hospitals' 340B Reimbursement
- Tribes From Wash., ND Pile Onto Opioid MDL
- 5 Firms To Steer IPOs Exceeding $3.9B, Led By Axa Unit
- Fed. Circ. Revives Row Over Origin Of Hair-Removal Patent
- Pharma Execs Cast Doubt On Valeant's Compliance Culture
- Loeb & Loeb Atty Says Shkreli Defamed Her While At Turing
- Pa. Judge OKs Redo In Flaherty Fardo Malpractice Row
- Last Insurer Settles With Mylan In $67M Antitrust Appeal
- Doctor Escapes Suit Over Shoddy Biomet Hip Replacements
- Cybersecurity Firm Carbon Black Tops 8 IPOs Totaling $733M
- Perkins Coie Nabs Tech, VC Partner From DLA Piper
- Shire's $2.4M Fee Bid In Adderall Row Too High, Rival Says
- Practical Considerations For Litigating Proportionality
- Los Angeles Latest To Sue Pharma Cos. Over Opioid Crisis
- Docs' Attys Seek $5.7M From $13.5M Botox Pricing Deal
- $10M Philidor Trial Opens With Focus On Valeant Kickback
- FDA Chief Targets Kickback Safe Harbor To Trim Drug Prices
- Fed. Circ. Won't Revive Hip Implant Patent Nixed By PTAB
- Fox Rothschild Picks Up IP Pro For NY Office
- Feds Urged To Get Generic Naloxone, Patents Be Damned
- 8th Circ. Asked To Revive Express Scripts Antitrust Suit
- Generic Drug Patent Suits Up In 2017, Especially In Delaware
- What To Know About NIST's Bayh-Dole Act Updates
- Surveying The CRISPR Patent War
- Supporting Nontraditional Data Types In E-Discovery
- Fresenius' Hits Akorn With Counterclaims Alleging Fraud
- VC-Backed Medical Device Co. Prices Upsized $108M IPO
- Cholesterol Test Strip Co. Wants ITC To Investigate Rival
- Pharma Industry Seeks Texas MDL For Opioid Cases
- Mylan Settles With Most Insurers In $67M Antitrust Appeal
- Biotech Firm, Streaming Co. Launch IPOs Totaling $225M
- Opioid Cos. Sued Over Ballooning Health Insurance Costs
- Fed. Circ. Prods Teva On Bid To Revive Nixed Dose Patents
- Thoratec Investors Seek Cert. In Revived Stock-Drop Suit
- PharMerica Beats Final Claims In 2007 Kickback Lawsuit
- Calif. Regulator OKs First Policy For Pot Biz Landlords
- Honigman Nabs Dinsmore Partner, 2 Attys For IP Group
- NJ Real Estate Considerations After Cannabis Legalization
- Ex-Biotech Exec To Admit Lying To SEC, Skip Fraud Retrial
- J&J Subsidiary's Breast Implants Caused Cancer, Suit Says